SAN DIEGO, April 15 /PRNewswire/ -- NexBio, Inc. announced today that it
has completed the formation of a new Clinical Advisory Board (CAB) to
complement its existing group of Senior Advisers. NexBio recently completed a
First-In-Man clinical trial of DAS181 (Fludase(R)), an investigational drug
candidate for influenza. The new CAB will guide NexBio throughout the clinical
development of this novel medicine, helping the company to conduct advanced
product development to address the threat of a potential influenza pandemic.
The CAB is chaired by Andrew Pavia, M.D., who is joined by Robert Belshe, M.D.,
Kathryn Edwards, M.D., Allison McGeer, M.D., FRCPC, and Richard Whitley, M.D.

"These individuals are among the most highly regarded thought leaders in
the field of clinical development of drugs for respiratory viral infections,"
said Ron Moss, M.D., NexBio's Executive Vice President, Clinical Development &
Medical Affairs. "We expect that their depth of knowledge and experience will
contribute enormously to the goal of developing Fludase for the prevention and
treatment of Influenza-Like Illness caused by influenza, parainfluenza, and
potential pandemic strains such as H5N1. With the development of drug
resistance to currently licensed antivirals, our distinguished CAB recognizes
the importance of determining the clinical utility of DAS181 against emerging
strains of influenza."

Dr. Pavia is the George and Esther Gross Presidential Professor and Chief
of the Division of Pediatric Infectious Diseases at the University of Utah
Health Sciences Center. He is very active as an infectious disease
investigator and in policy. Dr. Pavia serves on several advisory committees
for federal and state government on vaccine policy, biodefense, and pandemic
influenza preparedness. He leads several committees of the Infectious
Diseases Society of America and has been a member of the Institute of Medicine
Committee on "Antivirals for Pandemic Influenza: Guidance on Developing a
Distribution and Dispensing Program." Dr. Pavia's research interests include
the epidemiology of influenza and other emerging infections; he has published
more than 100 scientific articles and chapters. He also has significant
experience in the clinical development of antiviral compounds.

Dr. Belshe is the Dianna and J. Joseph Adorjan Endowed Professor of
Infectious Diseases and Immunology; Professor of Medicine, Pediatrics and
Molecular Microbiology, and Director for the Division of Infectious Diseases
and Immunology, at the St. Louis University School of Medicine. He has
published numerous key clinical articles on influenza vaccines and
pathogenesis of influenza.

Dr. Edwards holds the Sarah H. Sell Endowed Professorship in Pediatrics at
Vanderbilt University School of Medicine. She has completed several peer
review publications and published many pivotal articles on infectious disease,
influenza vaccines and pathogenesis, and parainfluenza in pediatric patients.
Dr. Edwards is a current National Institute of Allergy and Infectious Diseases
(NIAID) Advisory Council member and has been awarded multiple grants.

Dr. McGeer is a Professor of Laboratory Medicine and Pathobiology at the
University of Toronto and Director of Infection Control and a Microbiologist
at the Mount Sinai Hospital, Toronto. Dr. McGeer is a practicing clinician
and has served on expert committees including the Council of Canadian
Academies Expert Panel on Influenza and Respiratory Protection, and the
Canadian National Advisory Committee on Immunization.

Dr. Whitley is the Loeb Eminent Scholar Chair in Pediatrics; Professor of
Pediatrics, Microbiology, Medicine and Neurosurgery; Co-Director, University
of Alabama at Birmingham Center for Emerging Infections and Emergency
Preparedness; Director, Division of Pediatric Infectious Diseases; and Vice-
Chairman, Department of Pediatrics. Dr. Whitley has served on several
editorial and advisory boards and is currently the Vice President and
President Elect for the Infectious Disease Society of America. Since 1980 Dr.
Whitley has served as the Project Director for NIAID's Collaborative Antiviral
Study Group, a multi-center clinical trial network directed to conduct studies
to evaluate novel antiviral therapies that target unmet medical needs.

More information on each CAB member may be found on the company's web site.
ABOUT NEXBIO

NexBio, Inc. is a privately held development-stage biopharmaceutical
company located in San Diego. NexBio's mission is to save lives and to improve
the quality of life by creating and commercializing novel, broad-spectrum
biopharmaceuticals to prevent and treat current and emerging life-threatening
diseases. DAS181 (Fludase(R)), a recombinant fusion protein, inactivates viral
receptors on the cells of the human respiratory tract, thereby preventing
influenza, including potential pandemic strains, and parainfluenza viruses
(which may cause serious respiratory illness similar to influenza and for
which there is no approved vaccine or therapeutic) from infecting the human
body or from amplifying in infected individuals. Unlike current antiviral
compounds and vaccines, DAS181 targets human host receptors, not virus
components, and thus carries a reduced risk of drug resistance compared with
the currently available antiviral drugs. Extensive, prolonged nonclinical
studies have not shown the development of any meaningful resistance.
Furthermore, DAS181 has been shown effective against influenza that is
resistant to Tamiflu(R). The DAS181 development program is funded by the
National Institute of Allergy and Infectious Diseases (NIAID), part of the
National Institutes of Health. Viradin(TM), invented and developed by NexBio,
is a parenteral protein under development, currently at lead optimization
stage, directed to the treatment of viral hemorrhagic fever caused by viruses
such as Ebola and Marburg, as well as the treatment of sepsis and septic shock.
TOSAP(TM) is a microparticle formulation technology invented and developed by
NexBio, used to formulate DAS181 for inhalation, as well as other NexBio
compounds and compounds of partners, under license.

This release contains forward-looking information about the research and
development program of NexBio and the potential efficacy of product candidates
that might result from programs that involve substantial risks and
uncertainties. Such risks and uncertainties include, among other things, the
uncertainties inherent in research and development activities; decisions by
regulatory authorities regarding whether and when to permit the clinical
investigation of or approve any drug applications that may result from the
programs as well as their decisions regarding labeling and other matters that
could affect the commercial potential of product candidates that may result
from the program; and competitive developments.

(Date:10/9/2017)... ... 2017 , ... The award-winning American Farmer television series will feature 3 Bar ... Tuesdays at 8:30aET on RFD-TV. , With global population estimates nearing ten billion ... continue to feed a growing nation. At the same time, many of our valuable ...

(Date:4/11/2017)... 11, 2017 No two people are ... the New York University Tandon School of Engineering ... found that partial similarities between prints are common ... mobile phones and other electronic devices can be ... vulnerability lies in the fact that fingerprint-based authentication ...

(Date:4/5/2017)... 2017 KEY FINDINGS The global ... a CAGR of 25.76% during the forecast period of ... factor for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is ... geography. The stem cell market of the product is ...

(Date:3/30/2017)... NEW YORK , March 30, 2017 ... by type (physiological and behavioral), by technology (fingerprint, AFIS, ... recognition, voice recognition, and others), by end use industry ... travel and immigration, financial and banking, and others), and ... Europe , Asia Pacific ...